Piper Sandler analyst Christopher Raymond lowered the firm’s price target on iTeos Therapeutics to $12 from $16 and keeps an Overweight rating on the shares. The firm notes belrestotug + dostarlimab failed to meet pre-specified PFS in the GALAXIES Lung-201 study and showed insufficient ORR in the H&N-202 study. iTeos (ITOS) and GSK (GSK) are discontinuing the belrestotug program including the Phase III Lung-301 trial, and evaluating strategic alternatives.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- Leerink downgrades iTeos Therapeutics after termination of TIGIT program
- iTeos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- iTeos Therapeutics downgraded to Market Perform from Outperform at Leerink
- Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth
- iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended